{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T02:33:01Z","timestamp":1787106781585,"version":"build-2736575974"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003443","name":"Ministry of Education and Science of the Russian Federation","doi-asserted-by":"publisher","award":["075-15-2024-536"],"award-info":[{"award-number":["075-15-2024-536"]}],"id":[{"id":"10.13039\/501100003443","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003443","name":"Ministry of Education and Science of the Russian Federation","doi-asserted-by":"publisher","award":["075-15-2024-536"],"award-info":[{"award-number":["075-15-2024-536"]}],"id":[{"id":"10.13039\/501100003443","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003443","name":"Ministry of Education and Science of the Russian Federation","doi-asserted-by":"publisher","award":["075-15-2024-536"],"award-info":[{"award-number":["075-15-2024-536"]}],"id":[{"id":"10.13039\/501100003443","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003443","name":"Ministry of Education and Science of the Russian Federation","doi-asserted-by":"publisher","award":["075-15-2024-536"],"award-info":[{"award-number":["075-15-2024-536"]}],"id":[{"id":"10.13039\/501100003443","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003443","name":"Ministry of Education and Science of the Russian Federation","doi-asserted-by":"publisher","award":["075-15-2024-536"],"award-info":[{"award-number":["075-15-2024-536"]}],"id":[{"id":"10.13039\/501100003443","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003443","name":"Ministry of Education and Science of the Russian Federation","doi-asserted-by":"publisher","award":["075-15-2024-536"],"award-info":[{"award-number":["075-15-2024-536"]}],"id":[{"id":"10.13039\/501100003443","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003443","name":"Ministry of Education and Science of the Russian Federation","doi-asserted-by":"publisher","award":["075-15-2024-536"],"award-info":[{"award-number":["075-15-2024-536"]}],"id":[{"id":"10.13039\/501100003443","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    NK cells are promising candidates for adoptive cell therapy; however, their proliferative capacity and functional persistence may be limited. Genetic modification with\n                    <jats:italic>hTERT<\/jats:italic>\n                    enhances their proliferative potential, while co-expression of the\n                    <jats:italic>iCASP9<\/jats:italic>\n                    suicide gene provides a safety mechanism based on late-stage apoptosis induction by chemical dimerizer (CID). Whether hTERT overexpression interferes with iCasp9-mediated cell death remains unclear, and the non-canonical functions of telomerase in this context are poorly understood. This study served a dual purpose: to assess the efficacy of the iCasp9 \u201csuicide switch\u201d in NK cells, and to investigate a non-canonical role of telomerase in NK cell-mediated evasion from cell death. Here, we demonstrate that hTERT-modified NK cells exhibit significant resistance to CID-induced apoptosis, an effect independent of telomerase catalytic activity, as confirmed using a dominant-negative hTERT (DN-hTERT) mutant. Transcriptomic profiling revealed that both CID-resistant iCasp9-NK cells and hTERT-iCasp9-NK cells share common gene expression signatures: upregulation of cell cycle-associated genes and downregulation of splicing-related factors, including\n                    <jats:italic>HNRNPH1<\/jats:italic>\n                    and\n                    <jats:italic>SNRPD3<\/jats:italic>\n                    , accompanied by shared patterns of alternative splicing. Among apoptosis-related transcripts,\n                    <jats:italic>BIRC3, which<\/jats:italic>\n                    encodes c-IAP-2, a direct inhibitor of caspase 9, was consistently elevated in both \u201cresistant\u201d and \u201csurvived\u201d NK cells. However, shRNA-mediated knockdown of\n                    <jats:italic>BIRC3<\/jats:italic>\n                    failed to restore sensitivity to CID, indicating that\n                    <jats:italic>BIRC3<\/jats:italic>\n                    upregulation is not the unique determinant of resistance and suggesting involvement of additional compensatory pathways. Overall, our findings define specific transcriptional signatures associated with evasion of NK cells from iCasp9-mediated apoptosis, implying the contribution of cell cycle progression, enhanced anti-apoptotic signaling, and alterations in splicing regulation, and highlighting the complex role of non-canonical hTERT functions in these adaptations. In the rational design of next-generation gene-modified NK cell therapies with improved safety and persistence, the uncovered insights should be considered.\n                  <\/jats:p>","DOI":"10.1038\/s41420-026-03183-y","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:55:59Z","timestamp":1781272559000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interplay of telomerase non-canonical functions in NK cell resistance to iCasp9-mediated apoptosis"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4470-4240","authenticated-orcid":false,"given":"Anastasia I.","family":"Palamarchuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3378-6508","authenticated-orcid":false,"given":"Maria O.","family":"Ustiuzhanina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7209-1373","authenticated-orcid":false,"given":"Rodion A.","family":"Velichinskii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia D.","family":"Vavilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria V.","family":"Grechikhina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8119-8247","authenticated-orcid":false,"given":"Elena I.","family":"Kovalenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5403-0753","authenticated-orcid":false,"given":"Maria A.","family":"Streltsova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"3183_CR1","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.3390\/cells10051058","volume":"10","author":"R Islam","year":"2021","unstructured":"Islam R, Pupovac A, Evtimov V, Boyd N, Shu R, Boyd R, et al. Enhancing a natural killer: modification of NK cells for cancer immunotherapy. Cells. 2021;10:1058.","journal-title":"Cells"},{"key":"3183_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-021-01083-5","volume":"14","author":"Y Gong","year":"2021","unstructured":"Gong Y, Klein Wolterink RGJ, Wang J, Bos GMJ, Germeraad WTV. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol. 2021;14:73.","journal-title":"J Hematol Oncol"},{"key":"3183_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.732135","volume":"12","author":"EL Heipertz","year":"2021","unstructured":"Heipertz EL, Zynda ER, Stav-Noraas TE, Hungler AD, Boucher SE, Kaur N, et al. Current perspectives on \u201cOff-The-Shelf\u201d allogeneic NK and CAR-NK cell therapies. Front Immunol. 2021;12:732135.","journal-title":"Front Immunol"},{"key":"3183_CR4","doi-asserted-by":"publisher","first-page":"5868","DOI":"10.1182\/bloodadvances.2020002547","volume":"4","author":"R Basar","year":"2020","unstructured":"Basar R, Daher M, Rezvani K. Next-generation cell therapies: the emerging role of CAR-NK cells. Blood Adv. 2020;4:5868\u201376.","journal-title":"Blood Adv"},{"key":"3183_CR5","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/j.1365-2141.2009.07667.x","volume":"145","author":"H Fujisaki","year":"2009","unstructured":"Fujisaki H, Kakuda H, Imai C, Mullighan CG, Campana D. Replicative potential of human natural killer cells. Br J Haematol. 2009;145:606\u201313.","journal-title":"Br J Haematol"},{"key":"3183_CR6","doi-asserted-by":"publisher","first-page":"662.","DOI":"10.3390\/biomedicines9060662","volume":"9","author":"MA Streltsova","year":"2021","unstructured":"Streltsova MA, Ustiuzhanina MO, Barsov EV, Kust SA, Velichinskii RA, Kovalenko EI. Telomerase reverse transcriptase increases the proliferation and lifespan of human NK cells without immortalization. Biomedicines. 2021;9:662.","journal-title":"Biomedicines"},{"key":"3183_CR7","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1158\/0008-5472.CAN-08-3712","volume":"69","author":"H Fujisaki","year":"2009","unstructured":"Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 2009;69:4010\u20137.","journal-title":"Cancer Res"},{"key":"3183_CR8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev-pathol-020712-164030","volume":"8","author":"L Xu","year":"2013","unstructured":"Xu L, Li S, Stohr BA. The role of telomere biology in cancer. Annu Rev Pathol. 2013;8:49\u201378.","journal-title":"Annu Rev Pathol"},{"key":"3183_CR9","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/0014-4827(65)90211-9","volume":"37","author":"L Hayflick","year":"1965","unstructured":"Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res. 1965;37:614\u201336.","journal-title":"Exp Cell Res"},{"key":"3183_CR10","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1182\/blood.V98.3.597","volume":"98","author":"N Rufer","year":"2001","unstructured":"Rufer N, Migliaccio M, Antonchuk J, Humphries RK, Roosnek E, Lansdorp PM. Transfer of the human telomerase reverse transcriptase (TERT) gene into T lymphocytes results in extension of replicative potential. Blood. 2001;98:597\u2013603.","journal-title":"Blood"},{"key":"3183_CR11","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1038\/ncb2621","volume":"14","author":"A Ghosh","year":"2012","unstructured":"Ghosh A, Saginc G, Leow SC, Khattar E, Shin EM, Yan TD, et al. Telomerase directly regulates NF-\u03baB-dependent transcription. Nat Cell Biol. 2012;14:1270\u201381.","journal-title":"Nat Cell Biol"},{"key":"3183_CR12","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/nature08137","volume":"460","author":"J-I Park","year":"2009","unstructured":"Park J-I, Venteicher AS, Hong JY, Choi J, Jun S, Shkreli M, et al. Telomerase modulates Wnt signalling by association with target gene chromatin. Nature. 2009;460:66\u201372.","journal-title":"Nature"},{"key":"3183_CR13","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1158\/0008-5472.CAN-10-1588","volume":"71","author":"IR Indran","year":"2011","unstructured":"Indran IR, Hande MP, Pervaiz S. hTERT overexpression alleviates intracellular ROS production, improves mitochondrial function, and inhibits ROS-mediated apoptosis in cancer cells. Cancer Res. 2011;71:266\u201376.","journal-title":"Cancer Res"},{"key":"3183_CR14","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1474-9728.2004.00124.x","volume":"3","author":"JH Santos","year":"2004","unstructured":"Santos JH, Meyer JN, Skorvaga M, Annab LA, Van Houten B. Mitochondrial hTERT exacerbates free-radical-mediated mtDNA damage. Aging Cell. 2004;3:399\u2013411.","journal-title":"Aging Cell"},{"key":"3183_CR15","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1038\/sj.onc.1205419","volume":"21","author":"Y Cao","year":"2002","unstructured":"Cao Y, Li H, Deb S, Liu J-P. TERT regulates cell survival independent of telomerase enzymatic activity. Oncogene. 2002;21:3130\u20138.","journal-title":"Oncogene"},{"key":"3183_CR16","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/sj.onc.1208232","volume":"24","author":"R Rahman","year":"2005","unstructured":"Rahman R, Latonen L, Wiman KG. hTERT antagonizes p53-induced apoptosis independently of telomerase activity. Oncogene. 2005;24:1320\u20137.","journal-title":"Oncogene"},{"key":"3183_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13331","volume":"20","author":"Y Benslimane","year":"2021","unstructured":"Benslimane Y, S\u00e1nchez-Osuna M, Coulombe-Huntington J, Bertomeu T, Henry D, Huard C, et al. A novel p53 regulator, C16ORF72\/TAPR1, buffers against telomerase inhibition. Aging Cell. 2021;20:e13331.","journal-title":"Aging Cell"},{"key":"3183_CR18","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2147\/ciia.2006.1.2.155","volume":"1","author":"Y Bermudez","year":"2006","unstructured":"Bermudez Y, Erasso D, Johnson NC, Alfonso MY, Lowell NE, Kruk PA. Telomerase confers resistance to caspase-mediated apoptosis. Clin Inter Aging. 2006;1:155\u201367.","journal-title":"Clin Inter Aging"},{"key":"3183_CR19","first-page":"684","volume":"41","author":"Y Jin","year":"2018","unstructured":"Jin Y, You L, Kim HJ, Lee H-W. Telomerase reverse transcriptase contains a BH3-like motif and interacts with BCL-2 family members. Mol Cells. 2018;41:684\u201394.","journal-title":"Mol Cells"},{"key":"3183_CR20","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/nri890","volume":"2","author":"RJ Hodes","year":"2002","unstructured":"Hodes RJ, Hathcock KS, Weng N. Telomeres in T and B cells. Nat Rev Immunol. 2002;2:699\u2013706.","journal-title":"Nat Rev Immunol"},{"key":"3183_CR21","doi-asserted-by":"publisher","first-page":"e30264","DOI":"10.1371\/journal.pone.0030264","volume":"7","author":"CJ Denman","year":"2012","unstructured":"Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar PV, Kopp LM, Johnson JL, et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS ONE. 2012;7:e30264.","journal-title":"PLoS ONE"},{"key":"3183_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.594620","volume":"11","author":"F Watkinson","year":"2020","unstructured":"Watkinson F, Nayar SK, Rani A, Sakellariou CA, Elhage O, Papaevangelou E, et al. IL-15 Upregulates telomerase expression and potently increases proliferative capacity of NK, NKT-like, and CD8 T cells. Front Immunol. 2020;11:594620.","journal-title":"Front Immunol"},{"key":"3183_CR23","doi-asserted-by":"publisher","first-page":"5845","DOI":"10.4049\/jimmunol.179.9.5845","volume":"179","author":"Y Zhao","year":"2007","unstructured":"Zhao Y, Bennett AD, Zheng Z, Wang QJ, Robbins PF, Yu LYL, et al. High-affinity TCRs generated by phage display provide CD4\u2009+\u2009T cells with the ability to recognize and kill tumor cell lines. J Immunol. 2007;179:5845\u201354.","journal-title":"J Immunol"},{"key":"3183_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41417-018-0034-1","volume":"26","author":"F Rossignoli","year":"2019","unstructured":"Rossignoli F, Grisendi G, Spano C, Golinelli G, Recchia A, Rovesti G, et al. Inducible Caspase9-mediated suicide gene for MSC-based cancer gene therapy. Cancer Gene Ther. 2019;26:11\u20136.","journal-title":"Cancer Gene Ther"},{"key":"3183_CR25","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19\u2009+\u2009B cell tumors: a phase 1\/2 trial. Nat Med. 2024;30:772\u201384.","journal-title":"Nat Med"},{"key":"3183_CR26","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","volume":"365","author":"A Di Stasi","year":"2011","unstructured":"Di Stasi A, Tey S-K, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365:1673\u201383.","journal-title":"N Engl J Med"},{"key":"3183_CR27","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/aps.2017.125","volume":"39","author":"Y Hu","year":"2018","unstructured":"Hu Y, Tian Z-G, Zhang C. Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy. Acta Pharm Sin. 2018;39:167\u201376.","journal-title":"Acta Pharm Sin"},{"key":"3183_CR28","doi-asserted-by":"publisher","first-page":"23996","DOI":"10.18632\/oncotarget.15098","volume":"8","author":"P Li","year":"2017","unstructured":"Li P, Zhou L, Zhao T, Liu X, Zhang P, Liu Y, et al. Caspase-9: structure, mechanisms and clinical application. Oncotarget. 2017;8:23996\u20134008.","journal-title":"Oncotarget"},{"key":"3183_CR29","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1089\/hgtb.2012.050","volume":"23","author":"V Marin","year":"2012","unstructured":"Marin V, Cribioli E, Philip B, Tettamanti S, Pizzitola I, Biondi A, et al. Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells. Hum Gene Ther Methods. 2012;23:376\u201386.","journal-title":"Hum Gene Ther Methods"},{"key":"3183_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2014.11","volume":"3","author":"S-K Tey","year":"2014","unstructured":"Tey S-K. Adoptive T-cell therapy: adverse events and safety switches. Clin Transl Immunol. 2014;3:e17.","journal-title":"Clin Transl Immunol"},{"key":"3183_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04468-z","volume":"13","author":"Y Yuan","year":"2022","unstructured":"Yuan Y, Ren H, Li Y, Qin S, Yang X, Tang C. Cell-to-cell variability in inducible Caspase9-mediated cell death. Cell Death Dis. 2022;13:34.","journal-title":"Cell Death Dis"},{"key":"3183_CR32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/stem.1869","volume":"33","author":"CN Barese","year":"2015","unstructured":"Barese CN, Felizardo TC, Sellers SE, Keyvanfar K, Di Stasi A, Metzger ME, et al. Regulated apoptosis of genetically modified hematopoietic stem and progenitor cells via an inducible caspase-9 suicide gene in rhesus macaques. Stem Cells. 2015;33:91\u2013100.","journal-title":"Stem Cells"},{"key":"3183_CR33","doi-asserted-by":"publisher","first-page":"13326.","DOI":"10.3390\/ijms222413326","volume":"22","author":"AI Palamarchuk","year":"2021","unstructured":"Palamarchuk AI, Alekseeva NA, Streltsova MA, Ustiuzhanina MO, Kobyzeva PA, Kust SA, et al. Increased susceptibility of the CD57- NK cells expressing KIR2DL2\/3 and NKG2C to iCasp9 gene retroviral transduction and the relationships with proliferative potential, activation degree, and death induction response. Int J Mol Sci. 2021;22:13326.","journal-title":"Int J Mol Sci"},{"key":"3183_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25758-2","volume":"12","author":"J Zhang","year":"2021","unstructured":"Zhang J, Le Gras S, Pouxvielh K, Faure F, Fallone L, Kern N, et al. Sequential actions of EOMES and T-BET promote stepwise maturation of natural killer cells. Nat Commun. 2021;12:5446.","journal-title":"Nat Commun"},{"key":"3183_CR35","doi-asserted-by":"publisher","first-page":"e0126730","DOI":"10.1371\/journal.pone.0126730","volume":"10","author":"N Arish","year":"2015","unstructured":"Arish N, Cohen PY, Golan-Gerstl R, Fridlender Z, Dayan MR, Zisman P, et al. Overexpression of telomerase protects human and murine lung epithelial cells from fas- and bleomycin-induced apoptosis via FLIP upregulation. PLoS ONE. 2015;10:e0126730.","journal-title":"PLoS ONE"},{"key":"3183_CR36","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3389\/fnmol.2018.00160","volume":"11","author":"M-Y Liu","year":"2018","unstructured":"Liu M-Y, Nemes A, Zhou Q-G. The emerging roles for telomerase in the central nervous system. Front Mol Neurosci. 2018;11:160.","journal-title":"Front Mol Neurosci"},{"key":"3183_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1515718","volume":"16","author":"R Wu","year":"2025","unstructured":"Wu R, Yang H, Liu C. IFIT3: a crucial mediator in innate immunity and tumor progression with therapeutic implications. Front Immunol. 2025;16:1515718.","journal-title":"Front Immunol"},{"key":"3183_CR38","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1172\/JCI79134","volume":"125","author":"CM Koh","year":"2015","unstructured":"Koh CM, Khattar E, Leow SC, Liu CY, Muller J, Ang WX, et al. Telomerase regulates MYC-driven oncogenesis independent of its reverse transcriptase activity. J Clin Invest. 2015;125:2109\u201322.","journal-title":"J Clin Invest"},{"key":"3183_CR39","doi-asserted-by":"publisher","first-page":"8222","DOI":"10.1073\/pnas.0503095102","volume":"102","author":"K Masutomi","year":"2005","unstructured":"Masutomi K, Possemato R, Wong JMY, Currier JL, Tothova Z, Manola JB, et al. The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc Natl Acad Sci USA. 2005;102:8222\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3183_CR40","doi-asserted-by":"publisher","first-page":"mjac074.","DOI":"10.1093\/jmcb\/mjac074","volume":"14","author":"Q Hao","year":"2023","unstructured":"Hao Q, Chen J, Lu H, Zhou X. The ARTS of p53-dependent mitochondrial apoptosis. J Mol Cell Biol. 2023;14:mjac074.","journal-title":"J Mol Cell Biol"},{"key":"3183_CR41","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1038\/onc.2016.502","volume":"36","author":"M Fischer","year":"2017","unstructured":"Fischer M. Census and evaluation of p53 target genes. Oncogene. 2017;36:3943\u201356.","journal-title":"Oncogene"},{"key":"3183_CR42","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1038\/sj.cdd.4400594","volume":"6","author":"PG Ekert","year":"1999","unstructured":"Ekert PG, Silke J, Vaux DL. Caspase inhibitors. Cell Death Differ. 1999;6:1081\u20136.","journal-title":"Cell Death Differ"},{"key":"3183_CR43","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.4161\/cc.7.8.5783","volume":"7","author":"L Dubrez-Daloz","year":"2008","unstructured":"Dubrez-Daloz L, Dupoux A, Cartier J. IAPs: more than just inhibitors of apoptosis proteins. Cell Cycle. 2008;7:1036\u201346.","journal-title":"Cell Cycle"},{"key":"3183_CR44","doi-asserted-by":"publisher","first-page":"10057","DOI":"10.1073\/pnas.94.19.10057","volume":"94","author":"ZL Chu","year":"1997","unstructured":"Chu ZL, McKinsey TA, Liu L, Gentry JJ, Malim MH, Ballard DW. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc Natl Acad Sci USA. 1997;94:10057\u201362.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3183_CR45","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/path.6351","volume":"264","author":"M Mishima","year":"2024","unstructured":"Mishima M, Takai A, Takeda H, Iguchi E, Nakano S, Fujii Y, et al. TERT upregulation promotes cell proliferation via degradation of p21 and increases carcinogenic potential. J Pathol. 2024;264:318\u201331.","journal-title":"J Pathol"},{"key":"3183_CR46","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1371\/journal.pgen.0040010","volume":"4","author":"J Choi","year":"2008","unstructured":"Choi J, Southworth LK, Sarin KY, Venteicher AS, Ma W, Chang W, et al. TERT promotes epithelial proliferation through transcriptional control of a Myc- and Wnt-related developmental program. PLoS Genet. 2008;4:e10.","journal-title":"PLoS Genet"},{"key":"3183_CR47","doi-asserted-by":"publisher","first-page":"e0193182","DOI":"10.1371\/journal.pone.0193182","volume":"13","author":"J-I Roh","year":"2018","unstructured":"Roh J-I, Kim Y, Oh J, Kim Y, Lee J, Lee J, et al. Hexokinase 2 is a molecular bridge linking telomerase and autophagy. PLoS ONE. 2018;13:e0193182.","journal-title":"PLoS ONE"},{"key":"3183_CR48","doi-asserted-by":"publisher","first-page":"207","DOI":"10.32604\/biocell.2021.014728","volume":"46","author":"P Yang","year":"2022","unstructured":"Yang P, Zou Z, Gao X. STMN1 promotes the proliferation and inhibits the apoptosis of acute myeloid leukemia cells by activating the PI3K\/Akt pathway. Biocell. 2022;46:207\u201318.","journal-title":"Biocell"},{"key":"3183_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04036-5","volume":"12","author":"C Yoon","year":"2021","unstructured":"Yoon C, Lu J, Ryeom SW, Simon MC, Yoon SS. PIK3R3, part of the regulatory domain of PI3K, is upregulated in sarcoma stem-like cells and promotes invasion, migration, and chemotherapy resistance. Cell Death Dis. 2021;12:749.","journal-title":"Cell Death Dis"},{"key":"3183_CR50","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.282.5392.1318","volume":"282","author":"MH Cardone","year":"1998","unstructured":"Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science. 1998;282:1318\u201321.","journal-title":"Science"},{"key":"3183_CR51","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.theriogenology.2020.11.007","volume":"161","author":"L-X Cui","year":"2021","unstructured":"Cui L-X, Tian Y-Q, Hao H-S, Zou H-Y, Pang Y-W, Zhao S-J, et al. Knockdown of ASH1L methyltransferase induced apoptosis inhibiting proliferation and H3K36 methylation in bovine cumulus cells. Theriogenology. 2021;161:65\u201373.","journal-title":"Theriogenology"},{"key":"3183_CR52","doi-asserted-by":"publisher","first-page":"6143","DOI":"10.1093\/nar\/gkad361","volume":"51","author":"H-M Kim","year":"2023","unstructured":"Kim H-M, Kang B, Park S, Park H, Kim CJ, Lee H, et al. Forkhead box protein D2 suppresses colorectal cancer by reprogramming enhancer interactions. Nucleic Acids Res. 2023;51:6143\u201355.","journal-title":"Nucleic Acids Res"},{"key":"3183_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-34519-8","volume":"13","author":"S Yu","year":"2023","unstructured":"Yu S, Yang Y, Yang H, Peng L, Wu Z, Sun L, et al. Pancancer analysis of oncogenic BARX2 identifying its prognostic value and immunological function in liver hepatocellular carcinoma. Sci Rep. 2023;13:7560.","journal-title":"Sci Rep"},{"key":"3183_CR54","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/s41366-021-01020-z","volume":"46","author":"Y Chen","year":"2022","unstructured":"Chen Y, Gao L, Lin T, Pei X, Gao Q, Chen J, et al. C\/EBPZ modulates the differentiation and proliferation of preadipocytes. Int J Obes (Lond). 2022;46:523\u201334.","journal-title":"Int J Obes (Lond)"},{"key":"3183_CR55","doi-asserted-by":"publisher","first-page":"26332","DOI":"10.1074\/jbc.M101553200","volume":"276","author":"C Imbriano","year":"2001","unstructured":"Imbriano C, Bolognese F, Gurtner A, Piaggio G, Mantovani R. HSP-CBF is an NF-Y-dependent coactivator of the heat shock promoters CCAAT boxes. J Biol Chem. 2001;276:26332\u20139.","journal-title":"J Biol Chem"},{"key":"3183_CR56","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S1097-2765(00)00075-7","volume":"6","author":"L Zheng","year":"2000","unstructured":"Zheng L, Pan H, Li S, Flesken-Nikitin A, Chen PL, Boyer TG, et al. Sequence-specific transcriptional corepressor function for BRCA1 through a novel zinc finger protein, ZBRK1. Mol Cell. 2000;6:757\u201368.","journal-title":"Mol Cell"},{"key":"3183_CR57","doi-asserted-by":"publisher","first-page":"650.","DOI":"10.3390\/biomedicines12030650","volume":"12","author":"AI Palamarchuk","year":"2024","unstructured":"Palamarchuk AI, Kovalenko EI, Streltsova MA. The hTERT and iCasp9 transgenes affect EOMES and T-BET levels in NK cells, and the introduction of both genes improves NK cell proliferation in response to IL2 and IL15 stimulation. Biomedicines. 2024;12:650.","journal-title":"Biomedicines"},{"key":"3183_CR58","first-page":"713","volume":"42","author":"M Katoh","year":"2018","unstructured":"Katoh M. Multi\u2011layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT\/\u03b2\u2011catenin signaling activation (Review). Int J Mol Med. 2018;42:713\u201325.","journal-title":"Int J Mol Med"},{"key":"3183_CR59","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13046-021-01863-4","volume":"40","author":"E Koedoot","year":"2021","unstructured":"Koedoot E, van Steijn E, Vermeer M, Gonz\u00e1lez-Prieto R, Vertegaal ACO, Martens JWM, et al. Splicing factors control triple-negative breast cancer cell mitosis through SUN2 interaction and sororin intron retention. J Exp Clin Cancer Res. 2021;40:82.","journal-title":"J Exp Clin Cancer Res"},{"key":"3183_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.682859","volume":"11","author":"M Liu","year":"2021","unstructured":"Liu M, Yang L, Liu X, Nie Z, Zhang X, Lu Y, et al. HNRNPH1 is a novel regulator of cellular proliferation and disease progression in chronic myeloid leukemia. Front Oncol. 2021;11:682859.","journal-title":"Front Oncol"},{"key":"3183_CR61","doi-asserted-by":"publisher","first-page":"447","DOI":"10.4161\/nucl.1.6.13328","volume":"1","author":"JC Hofmann","year":"2010","unstructured":"Hofmann JC, Husedzinovic A, Gruss OJ. The function of spliceosome components in open mitosis. Nucleus. 2010;1:447\u201359.","journal-title":"Nucleus"},{"key":"3183_CR62","doi-asserted-by":"publisher","first-page":"5288","DOI":"10.1158\/0008-5472.CAN-19-1504","volume":"79","author":"X Song","year":"2019","unstructured":"Song X, Wan X, Huang T, Zeng C, Sastry N, Wu B, et al. SRSF3-regulated RNA alternative splicing promotes glioblastoma tumorigenicity by affecting multiple cellular processes. Cancer Res. 2019;79:5288\u2013301.","journal-title":"Cancer Res"},{"key":"3183_CR63","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3892\/ol.2021.13139","volume":"23","author":"J Xiong","year":"2022","unstructured":"Xiong J, Chen Y, Wang W, Sun J. Biological function and molecular mechanism of SRSF3 in cancer and beyond. Oncol Lett. 2022;23:21.","journal-title":"Oncol Lett"},{"key":"3183_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-015-0422-1","volume":"14","author":"X He","year":"2015","unstructured":"He X, Zhang P. Serine\/arginine-rich splicing factor 3 (SRSF3) regulates homologous recombination-mediated DNA repair. Mol Cancer. 2015;14:158.","journal-title":"Mol Cancer"},{"key":"3183_CR65","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.celrep.2018.12.004","volume":"26","author":"A Naguib","year":"2019","unstructured":"Naguib A, Sandmann T, Yi F, Watts RJ, Lewcock JW, Dowdle WE. SUPT4H1 depletion leads to a global reduction in RNA. Cell Rep. 2019;26:45\u201353.e4.","journal-title":"Cell Rep"},{"key":"3183_CR66","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.3892\/ijmm.2015.2350","volume":"36","author":"Z Yao","year":"2015","unstructured":"Yao Z, Hu K, Huang H, Xu S, Wang Q, Zhang P, et al. shRNA-mediated silencing of the RFC3 gene suppresses hepatocellular carcinoma cell proliferation. Int J Mol Med. 2015;36:1393\u20139.","journal-title":"Int J Mol Med"},{"key":"3183_CR67","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.3892\/ol.2015.2900","volume":"9","author":"T-M Yuan","year":"2015","unstructured":"Yuan T-M, Liang R-Y, Chueh PJ, Chuang S-M. Role of ribophorin II in the response to anticancer drugs in gastric cancer cell lines. Oncol Lett. 2015;9:1861\u20138.","journal-title":"Oncol Lett"},{"key":"3183_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2023.102329","volume":"83","author":"G Sari","year":"2023","unstructured":"Sari G, Rock KL. Tumor immune evasion through loss of MHC class-I antigen presentation. Curr Opin Immunol. 2023;83:102329.","journal-title":"Curr Opin Immunol"},{"key":"3183_CR69","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4576789","volume":"2022","author":"T Song","year":"2022","unstructured":"Song T, Zhang H. RBM8A depletion decreases the cisplatin resistance and represses the proliferation and metastasis of breast cancer cells via akt\/mtor pathway. Breast J. 2022;2022:4576789.","journal-title":"Breast J"},{"key":"3183_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.688388","volume":"9","author":"M Alfaidi","year":"2021","unstructured":"Alfaidi M, Scott ML, Orr AW. Sinner or saint? nck adaptor proteins in vascular biology. Front Cell Dev Biol. 2021;9:688388.","journal-title":"Front Cell Dev Biol"},{"key":"3183_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1111522","volume":"13","author":"MG Matherne","year":"2023","unstructured":"Matherne MG, Phillips ES, Embrey SJ, Burke CM, Machado HL. Emerging functions of C\/EBP\u03b2 in breast cancer. Front Oncol. 2023;13:1111522.","journal-title":"Front Oncol"},{"key":"3183_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1107239","volume":"14","author":"J-Y Zhao","year":"2023","unstructured":"Zhao J-Y, Yuan X-K, Luo R-Z, Wang L-X, Gu W, Yamane D, et al. Phospholipase A and acyltransferase 4\/retinoic acid receptor responder 3 at the intersection of tumor suppression and pathogen restriction. Front Immunol. 2023;14:1107239.","journal-title":"Front Immunol"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03183-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03183-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03183-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T02:01:51Z","timestamp":1787104911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03183-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3183"],"URL":"https:\/\/doi.org\/10.1038\/s41420-026-03183-y","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"22 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Pirogov Russian National Research Medical University (protocol #252 from 25 June 2025).","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"340"}}